---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABX464-001"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABX464-001. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 15 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abx464-001"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABX464-001

<a id="heading-3.1.15"></a>

## 3.1.15 ABX464-001

<a id="heading-3.1.15.1"></a>

### 3.1.15.1 Objective

<a id="topic-3.1.15.1-1"></a>

#### Objective stated in the publication abstract

> “A first-in-man study was conducted to determine the pharmacokinetic and safety profiles of ABX464.”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

<a id="heading-3.1.15.2"></a>

### 3.1.15.2 Location and Study Date

<a id="topic-3.1.15.2-1"></a>

#### Single site in Montpellier, France

> “This study is an open label, parallel group, single ascending dose, exploratory study performed in a single site (Centre Cap, Montpellier, France).”

Source: [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)

<a id="topic-3.1.15.2-2"></a>

#### Study dates and status in the registry record

| Field | Registry entry |
| --- | --- |
| Recruitment status | “Completed” |
| Study start | “2014-03” |
| Primary completion (actual) | “2014-07” |
| Other study ID numbers | “ABX464-001” |

Source: [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)

<a id="heading-3.1.15.3"></a>

### 3.1.15.3 Study Design

<a id="topic-3.1.15.3-1"></a>

#### Open-label, single ascending dose design with sentinel dosing

> “Six subjects per dose group were enrolled into 1 of 4 groups with escalating doses of ABX464 (50, 100, 150 and 200 mg). For each dose group, a first subject was treated, if no adverse event (AE) occurred, a second subject was dosed one hour later. The four last subjects were dosed the day after if no clinically significant AE occurred. Escalation to the following dose level was decided after review of PK and safety data (laboratory results, ECG, vital signs and AEs)”

Source: [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)

<a id="heading-3.1.15.4"></a>

### 3.1.15.4 Eligibility Criteria

<a id="topic-3.1.15.4-1"></a>

#### Healthy men without HIV infection

> “Twenty-four male subjects in good health without HIV infection, aged from 18 to 55 years old, with BMIs of 18-27 kg/m 2 were included.”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

<a id="topic-3.1.15.4-2"></a>

#### Key criteria in the registry record

> “Non smokers or light smokers of less than 10 cigarettes per day”
> “Subject with any on-going infection or disease”

Source: [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)

<a id="heading-3.1.15.5"></a>

### 3.1.15.5 Treatment

<a id="topic-3.1.15.5-1"></a>

#### Single oral dose of 50 to 200 mg after overnight fasting

> “A single oral dose of ABX464 (50, 100, 150 or 200 mg) was administered on the morning of day 0 after overnight fasting, with follow-up for 45 days.”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

<a id="heading-3.1.15.6"></a>

### 3.1.15.6 Study Outcomes

<a id="heading-3.1.15.6.1"></a>

#### 3.1.15.6.1 Rationale for Using the Percentage of Participants With at Least One Adverse Event as the Primary Endpoint

<a id="topic-3.1.15.6.1-1"></a>

##### Registered primary and secondary outcomes

| Outcome | Measure | Time frame |
| --- | --- | --- |
| Primary | “Percentage of patients experiencing at least one Adverse Event” | “Up to 45 days post dosing” |
| Secondary | “Peak Plasma Concentrations (Cmax) of ABX464 and metabolite” | “Up to 45 days post dosing” |
| Secondary | “Area Under the Curve (AUC) of Plasma Concentrations of ABX464 and metabolite” | “Up to 45 days post dosing” |

Source: [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)

<a id="topic-3.1.15.6.1-2"></a>

##### Safety assessments and pharmacokinetic analytes

> “Safety assessments consisted of vital signs, electrocardiogram, physical examination, laboratory tests and urinalysis. Pharmacokinetic parameters were calculated for ABX464 and its main metabolite ABX-464- N -glucuronide (ABX464-NGlc).”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

<a id="heading-3.1.15.7"></a>

### 3.1.15.7 Statistical Analysis Description

<a id="heading-3.1.15.7.1"></a>

#### 3.1.15.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.15.7.1-1"></a>

##### Enrollment in the registry record

| Field | Registry entry |
| --- | --- |
| Enrollment (actual) | “24” |

Source: [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)

<a id="heading-3.1.15.7.2"></a>

#### 3.1.15.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.15.8"></a>

### 3.1.15.8 Results

<a id="heading-3.1.15.8.1"></a>

#### 3.1.15.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.15.8.2"></a>

#### 3.1.15.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.15.8.3"></a>

#### 3.1.15.8.3 Efficacy Results

<a id="topic-3.1.15.8.3-1"></a>

##### Pharmacokinetics of obefazimod and its N-glucuronide metabolite

> “ABX464's Cmax was observed approximately 2 h after administration in all groups. ABX464 was rapidly and substantially metabolized into ABX464-NGlc. The Cmax of ABX464-NGlc was observed approximately 4 h post-dose and was about 160-fold higher than that of the parent with a much longer t1/2 (90-110 h). The ratio of metabolite to parent drug was consistent across the complete dose range.”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

<a id="heading-3.1.15.8.4"></a>

#### 3.1.15.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.15.8.5"></a>

#### 3.1.15.8.5 Safety Results

<a id="topic-3.1.15.8.5-1"></a>

##### Tolerability across the 50 to 200 mg doses

> “ABX464 was well tolerated; the most frequent related treatment-emergent adverse events were headaches, nausea and vomiting; they were not considered as treatment-limiting effects.”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

<a id="topic-3.1.15.8.5-2"></a>

##### Description of the first-in-human results in the food-effect publication

> “This study was carried out with a single dose of 50, 100, 150, or 200 mg after overnight fasting, and the product was reported to be safe and well tolerated at all doses.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.15.9"></a>

### 3.1.15.9 Study Limitations

<a id="topic-3.1.15.9-1"></a>

#### Summary

ABX464-001 gave a single oral dose of 50, 100, 150, or 200 mg after overnight fasting to 24 healthy men, 6 per dose group. It had no placebo group and no repeated dosing, enrolled men only, and all doses were given fasted. The full article is closed access, and the abstract gives no numerical pharmacokinetic parameters by dose, no adverse event counts, and no dose-proportionality analysis beyond stating that the metabolite-to-parent ratio “was consistent across the complete dose range”. The registry record posts no results, and four of eight authors list Abivax as their affiliation.

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/); [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)

<a id="topic-3.1.15.9-2"></a>

#### Author affiliations in the abstract record

> “Scherrer D(1), Rouzier R(2), Noel Barrett P(3), Steens JM(1), Gineste P(1), Murphy RL(4), Tazi J(5), Ehrlich HJ(1).”
> “(1)ABIVAX, 5 Rue de la Baume, 75008 Paris, France.”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
